|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.22 USD | -0.09% |
|
-4.55% | +5.99% |
| 11:29pm | Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating | MT |
| 22/07 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | Other Pharmaceuticals | -0.18% | -4.55% | +5.99% | +14.56% | +88.49% | 162B |  |  | |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
